<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn></journal-meta><article-meta><article-id pub-id-type="pmid">766800</article-id><article-id pub-id-type="pmc">2025018</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Chemotherapy of advanced breast cancer: a controlled randomized trial of cyclophosphamide versus a four-drug combination.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Rubens</surname><given-names>R. D.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Knight</surname><given-names>R. K.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Hayward</surname><given-names>J. L.</given-names></name></contrib></contrib-group><pub-date pub-type="ppub"><month>12</month><year>1975</year></pub-date><volume>32</volume><issue>6</issue><fpage>730</fpage><lpage>736</lpage><abstract><p>Ninety-nine patients with advanced breast cancer were randomized to receive either cyclophosphamide continuously or a combination of cyclophosphamide, methotrexate, 5-fluorouracil and vinblastine given intermittently. The number and duration of objective responses were greater in patients receiving the combination but the differences between the two treatments did not achieve formal significance. The combination was logistically easier to manage and produced less toxicity.</p></abstract></article-meta></front><body><supplementary-material content-type="scanned-pages"><graphic xlink:href="brjcancer00321-0094.tif" xlink:title="scanned-page" xlink:role="730" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00321-0095.tif" xlink:title="scanned-page" xlink:role="731" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00321-0096.tif" xlink:title="scanned-page" xlink:role="732" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00321-0097.tif" xlink:title="scanned-page" xlink:role="733" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00321-0098.tif" xlink:title="scanned-page" xlink:role="734" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00321-0099.tif" xlink:title="scanned-page" xlink:role="735" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00321-0100.tif" xlink:title="scanned-page" xlink:role="736" mimetype="image" mime-subtype="tiff"/></supplementary-material></body></article>

